Home › NCT07718347

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

A Multi-center, Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser for the Tolerability and Improvement in the Appearance of Aging Skin.

Who can join

Ages 40 to 70 · All sexes

Inclusion Criteria

-:Adults 40-65 70 years

* Glogau III-IV
* Fitzpatrick II-IV.
* Suitable for ablative laser
* non-smoker ≥ 3 years
* Willing to comply with post-procedure regimen
* patient reported outcome documentation, and photo documentation.

Exclusion Criteria:

* Fitzpatrick I or \> IV,
* recent facial procedures (\< 6 months)
* active skin disease
* pregnancy/lactation
* implanted devices
* history of keloids.

About the study

ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.

What is being tested

• ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF). (other)

Sponsor: Lynch Regenerative Medicine · Participants: 21 · Started: Apr 16, 2026

Contact the study team

• Josh Arnold · Phone: 302-604-4532

Official record on ClinicalTrials.gov — NCT07718347

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.